🔎 Trials Near Me

Pradžia › Limfoma › Džordžija

Limfoma klinikiniai tyrimai Džordžija

16 tyrimai dėl Limfoma ieško dalyvių vietose Džordžija.

Miestai Džordžija

Oficialus tyrimo tekstas (anglų kalba)

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 0 iki 38 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06131801

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

  • Emory University Medical Center, Atlanta
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07192471

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  • Children's Healthcare of Atlanta - Egleston Hospital, Atlanta
Renkami dalyviai1/2 fazė
Iki 25 metų · Visoms lytims · Atnaujinta 2026-09-25 · NCT04094610

Collection of Tissue Samples for Cancer Research

  • Emory University, Atlanta
Renkami dalyviaiStebimasis tyrimas
2 Months · Visoms lytims · Atnaujinta 2026-09-16 · NCT00900198

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Renkami dalyviai1/2 fazė
12 Months – 21 Years · Visoms lytims · Atnaujinta 2026-09-11 · NCT04870944

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • City of Hope - Atlanta, Newnan
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-03 · NCT04588922

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Augusta University Medical Center, Augusta
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT05826535

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  • Winship Cancer Institute of Emory University, Atlanta
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-19 · NCT04104776

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Northside Hospital, Atlanta
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-04 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Winship Cancer Institute of Emory University, Atlanta
  • Georgia Cancer Center at Augusta University, Augusta
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-13 · NCT04792489

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

  • Emory University Hospital, Atlanta
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-08 · NCT07465835

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • Winship Cancer Institute of Emory University, Atlanta
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-02 · NCT05131022

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Children's Healthcare of Atlanta - Egleston, Atlanta
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-05-18 · NCT01790152

Pilot Imaging Study of Leukemia

  • Emory University, Atlanta
Renkami dalyviai1 fazė
Amžius nuo 4 iki 80 · Visoms lytims · Atnaujinta 2026-04-23 · NCT03633955

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

  • City of Hope Atlanta, Newnan
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-27 · NCT06915246

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • North Georgia Health System, Gainesville
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius 40 ir vyresni · Visoms lytims · Atnaujinta 2026-01-20 · NCT05366881

Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.